Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Código QR

Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Guardado en:

Detalles Bibliográficos
Autores principales:	Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/d43d6cb5eed04adbaa9c7c0324c11d5c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Florie Bertrand, et al.
Publicado: (2017)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Elena Galvani, et al.
Publicado: (2020)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Robert A. Szczepaniak Sloane, et al.
Publicado: (2021)

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
por: Seungwon Yang, et al.
Publicado: (2019)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: N. Jacquelot, et al.
Publicado: (2017)

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
por: Zhiyong Wang, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017)

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
por: Arwa Alkaraki, et al.
Publicado: (2021)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Nitin Roper, et al.
Publicado: (2021)

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
por: Jin Zhou, et al.
Publicado: (2017)

Molecular determinants of response to PD-L1 blockade across tumor types
por: Romain Banchereau, et al.
Publicado: (2021)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chun-Yu Chen, et al.
Publicado: (2017)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Yaohui Gao, et al.
Publicado: (2021)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation
por: Ines Martinez-Corral, et al.
Publicado: (2020)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression
por: Yao Chen, et al.
Publicado: (2017)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Shohei Koyama, et al.
Publicado: (2016)

Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
por: Hongji Zhang, et al.
Publicado: (2021)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
por: Li Wang, et al.
Publicado: (2018)

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
por: Darci Phillips, et al.
Publicado: (2021)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021)

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
por: Krista Dubin, et al.
Publicado: (2016)

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
por: Johannes Griss, et al.
Publicado: (2019)

Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
por: Catherine T. Flores, et al.
Publicado: (2018)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Khashayar Esfahani, et al.
Publicado: (2019)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Yi Liu, et al.
Publicado: (2021)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: Grégoire de Streel, et al.
Publicado: (2020)

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
por: Victoria Klepsch, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
por: Neta Rosenzweig, et al.
Publicado: (2019)

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
por: Manisha Singh, et al.
Publicado: (2017)

Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
por: Alexander Roberts, et al.
Publicado: (2021)

Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
por: Naoya Maekawa, et al.
Publicado: (2014)

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
por: Zia Khan, et al.
Publicado: (2021)

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
por: Qi Peng, et al.
Publicado: (2020)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Corey Smith, et al.
Publicado: (2021)

PD-1 immune checkpoint blockade may be viable for the prevention and treatment of elderly patients with POCD [Letter]
por: Wei P, et al.
Publicado: (2019)

Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth
por: Mari B. Ishak Gabra, et al.
Publicado: (2020)